A Phase 1 interventional study of MK-4250 in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-10-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-4250 monotherapy in anti-retroviral therapy (ART)-naïve, HIV-1 infected participants. The primary hypothesis of the study is that at a dose that is sufficiently safe and generally well tolerated, MK-4250 has superior antiretroviral activity compared to a historical placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) (log10 copies/mL) at 168 hours postdose.
The study consists of 5 panels; Panel C (MK-4250 ≤600 mg) was removed from the study with Protocol Amendment 1.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
Drug: MK-4250
Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
Drug: MK-4250
Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
Drug: MK-4250
Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
Drug: MK-4250
Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
Drug: MK-4250
MK-4250 tablets for oral administration
Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours
Plasma HIV-1 RNA was measured at Baseline and 168 hours after dosing. The log10 plasma HIV-RNA copies/mL measurements from participants in each panel were pooled and analyzed based on a longitudinal data analysis model. The change from Baseline in plasma HIV-1 RNA in participants administered MK-4250 was compared with historical placebo data.
Time frame: Baseline and Day 7
Percentage of Participants Experiencing ≥1 Adverse Events (AE)
The percentage of participants experiencing ≥1 AE was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.
Time frame: Up to Day 14
Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)
The percentage of participants who discontinued from the study due to an adverse event was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.
Time frame: Up to Day 14
Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250
The area under the concentration-time curve up to the last measurable concentration (AUC0-last) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250
The area under the concentration-time curve extrapolated to infinity (AUC0-inf) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250
The area under the concentration-time curve up to 168 hours (AUC0-168) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, and 168 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time.
Maximum Concentration (Cmax) of MK-4250 Reached in Plasma
The maximum concentration (Cmax) of MK-4250 in plasma was observed.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Concentration of MK-4250 at 168 Hours (C168hr)
The concentration of MK-4250 at 168 hours postdose (C168hr) was observed.
Time frame: 168 hours after administration of MK-4250.
Apparent Terminal Half-life (t1/2) of MK-4250
The apparent terminal half-life (t1/2) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Apparent Clearance (CL/F) of MK-4250
The apparent clearance (CL/F) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Apparent Volume of Distribution (Vz/F) of MK-4250
The apparent volume of distribution (Vz/F) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma
The time to maximum concentration (Vz/F) of MK-4250 in plasma was calculated.
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 120, 168, 192, and 240 hours after administration of MK-4250. For Panel B only, the first three participants additionally had a 72-hour postdose time, and no 240-hour postdose time.
| Milestone | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 0 |
| Completed | 6 | 6 | 6 | 6 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Plasma HIV-1 RNA was measured at Baseline and 168 hours after dosing. The log10 plasma HIV-RNA copies/mL measurements from participants in each panel were pooled and analyzed based on a longitudinal data analysis model. The change from Baseline in plasma HIV-1 RNA in participants administered MK-4250 was compared with historical placebo data.
| log10 copies per mL | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 Hours | -1.56 (-1.88 to -1.23) | -1.76 (-2.08 to -1.43) | -1.55 (-1.87 to -1.23) | -1.78 (-2.10 to -1.45) | — |
The percentage of participants experiencing ≥1 AE was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.
| Percentage of Participants | Screening | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|---|
| Percentage of Participants Experiencing ≥1 Adverse Events (AE) | 8.3 | 83.3 | 66.7 | 83.3 | 66.7 | — |
The percentage of participants who discontinued from the study due to an adverse event was calculated. An AE was defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy could be determined.
| Percentage of Participants | Screening | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
The area under the concentration-time curve up to the last measurable concentration (AUC0-last) of MK-4250 in plasma was calculated.
| μM·hour | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From 0 to Last Measurable Concentration (AUC0-last) for MK-4250 | 774 ± 54 | 2040 ± 17.1 | 2390 ± 35 | 3860 ± 44.3 | — |
The area under the concentration-time curve extrapolated to infinity (AUC0-inf) of MK-4250 in plasma was calculated.
| μM·hour | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From 0 to Infinity (AUC0-inf) for MK-4250 | 785 ± 54.6 | 2120 ± 18.4 | 2450 ± 35.9 | 4010 ± 47.6 | — |
The area under the concentration-time curve up to 168 hours (AUC0-168) of MK-4250 in plasma was calculated.
| μM·Hour | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) for MK-4250 | 751 ± 52.6 | 1980 ± 16.7 | 2280 ± 34.1 | 3640 ± 41.2 | — |
The maximum concentration (Cmax) of MK-4250 in plasma was observed.
| μM | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of MK-4250 Reached in Plasma | 16.6 ± 46.7 | 37.6 ± 26 | 43.5 ± 32.7 | 65 ± 25.8 | — |
The concentration of MK-4250 at 168 hours postdose (C168hr) was observed.
| μM | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Concentration of MK-4250 at 168 Hours (C168hr) | 0.558 ± 117 | 2.2 ± 57.4 | 2.38 ± 63.8 | 4.37 ± 96.4 | — |
The apparent terminal half-life (t1/2) of MK-4250 in plasma was calculated.
| Hours | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of MK-4250 | 35.9 ± 22.9 | 38.5 ± 31.9 | 44.1 ± 17.1 | 48.4 ± 32.1 | — |
The apparent clearance (CL/F) of MK-4250 in plasma was calculated.
| Liters/Hour | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of MK-4250 | 0.456 ± 54.6 | 0.676 ± 18.4 | 0.879 ± 35.9 | 0.536 ± 47.6 | — |
The apparent volume of distribution (Vz/F) of MK-4250 in plasma was calculated.
| Liters | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of MK-4250 | 23.6 ± 45.1 | 37.6 ± 23.5 | 56 ± 31.7 | 37.4 ± 17.5 | — |
The time to maximum concentration (Vz/F) of MK-4250 in plasma was calculated.
| Hours | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal |
|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-4250 Reached in Plasma | 4.00 (1.00 to 4.00) | 4.00 (4.00 to 6.00) | 4.00 (4.00 to 6.00) | 4.00 (4.00 to 8.00) | — |
Collected over Up to 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Screening | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| Panel A: 150 mg MK-4250 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel B: 600 mg MK-4250 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Panel D: 900 mg MK-4250 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel E: 900 mg MK-4250, With a Low Fat Meal | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Screening | Panel A: 150 mg MK-4250 | Panel B: 600 mg MK-4250 | Panel D: 900 mg MK-4250 | Panel E: 900 mg MK-4250, With a Low Fat Meal |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/24 | 4/6 | 2/6 | 1/6 | 3/6 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 1/6 | 3/6 | 1/6 | 0/6 |
| NasopharyngitisInfections and infestations | 0/24 | 3/6 | 0/6 | 1/6 | 0/6 |
| Aphthous ulcerGastrointestinal disorders | 0/24 | 0/6 | 0/6 | 2/6 | 0/6 |
| DizzinessNervous system disorders | 0/24 | 2/6 | 0/6 | 1/6 | 0/6 |
| LymphadenitisBlood and lymphatic system disorders | 0/24 | 0/6 | 0/6 | 1/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/24 | 0/6 | 1/6 | 0/6 | 0/6 |
| Dry mouthGastrointestinal disorders | 0/24 | 0/6 | 0/6 | 1/6 | 0/6 |
| NauseaGastrointestinal disorders | 0/24 | 1/6 | 1/6 | 0/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/24 | 1/6 | 1/6 | 0/6 | 0/6 |
Panel F did not enroll because the scientific objectives were met following completion of Panel E.
| Age, Continuous(Years) | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal | Total |
|---|---|---|---|---|---|---|
| Mean | 36.3 ± 8.1 | 32.5 ± 6.1 | 36.5 ± 8.9 | 35.5 ± 7.3 | — | 35.2 ± 7.3 |
| Sex: Female, Male(Participants) | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 0 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 5 | 6 | 6 | 6 | 0 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 6 | 0 | 24 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline Plasma HIV-1 Ribonucleic Acid (RNA)(log10 copies/mL) | Panel A: MK-4250 150 mg | Panel B: MK-4250 600 mg | Panel D: MK-4250 900 mg | Panel E: MK-4250 ≤900 mg With a Low-fat Meal | Panel F: MK-4250 ≤900 mg With a Moderate-fat Meal | Total |
|---|---|---|---|---|---|---|
| Mean | 4.29394 ± 0.41200 | 4.42577 ± 0.39577 | 4.85677 ± 0.23790 | 4.42262 ± 0.37308 | — | 4.49978 ± 0.40099 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2018 to primary completion in Nov 2018, 9 months.
Results were first posted in Oct 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.